EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Thrombospondin 2 is a key determinant of fibrogenesis in non‐alcoholic fatty liver disease

Takefumi Kimura iD, Takanobu Iwadare, Shun-Ichi Wakabayashi, Seema Kuldeep, Tomoyuki Nakajima, Tomoo Yamazaki, Daiki Aomura, Hamim Zafar, Mai Iwaya, Satoru Joshita, Takeshi Uehara, Sai P Pydi und 2 weitere

Liver International · 2024-02 · 44 (2) · 483-496

DOI: 10.1111/liv.15792 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, online erschienen am 27.11.2023. Verfasst von Takefumi Kimura und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto, Japan. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Thrombospondins. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AMED, JSPS KAKENHI, Aiba Works Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Hepatic overexpression of the thrombospondin 2 gene (THBS2) and elevated levels of circulating thrombospondin 2 (TSP2) have been observed in patients with chronic liver disease. This study aimed to identify the specific cells expressing THBS2/TSP2 in non‐alcoholic fatty liver disease (NAFLD) and investigate the underlying mechanism behind THBS2/TSP2 upregulation.

Design

Comprehensive NAFLD liver gene datasets, including single‐cell RNA sequencing (scRNA‐seq), in‐house NAFLD liver tissue, and LX‐2 cells derived from human hepatic stellate cells (HSCs), were analysed using a combination of computational biology, genetic, immunological, and pharmacological approaches.

Results

Analysis of the genetic dataset revealed the presence of 1433 variable genes in patients with advanced fibrosis NAFLD, with THBS2 ranked among the top 2 genes. Quantitative polymerase chain reaction (qPCR) examination of NAFLD livers showed a significant correlation between THBS2 expression and fibrosis stage ( r = .349, p < .001). In support of this, scRNA‐seq data and in situ hybridization demonstrated that the THBS2 gene was highly expressed in HSCs of NAFLD patients with advanced fibrosis. Pathway analysis of the gene dataset revealed THBS2 expression to be associated with the transforming growth factor beta (TGFβ) pathway and collagen gene activation. Moreover, the activation of LX‐2 cells with TGFβ increased THBS2/TSP2 and collagen expression independently of the TGFβ‐SMAD2/3 pathway. THBS2 gene knockdown significantly decreased collagen expression in LX‐2 cells.

Conclusions

THBS2/TSP2 is highly expressed in HSCs and plays a role in regulating fibrogenesis in NAFLD patients. THBS2/TSP2 may therefore represent a potential target for anti‐fibrotic therapy in NAFLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseThrombospondinsHumansLiverFibrosisTransforming Growth Factor betaHepatic Stellate CellsCollagenLiver CirrhosisThrombospondin 2

Stichwörter der Autor:innen

FibrosisNAFLDTHBS2TSP2Thrombospondin 2

Substanzen

Transforming Growth Factor betaCollagenThrombospondinsThrombospondin 2

Autor:innen und Institutionen

  • Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto, Japan.
  • Consultation Center for Liver Diseases, Shinshu University Hospital, Matsumoto, Japan.
  • Department of Biological Sciences and Bioengineering, Indian Institute of Technology, Kanpur, India.
  • Department of Laboratory Medicine, Shinshu University School Hospital, Matsumoto, Japan.
  • Department of Medicine, University of California San Diego, San Diego, La Jolla, USA.
  • Department of Medicine, Division of Nephrology, Shinshu University School of Medicine, Matsumoto, Japan.

ORCID-Profile: Takefumi Kimura, Takeji Umemura

Förderung

  • AMED
  • JSPS KAKENHI
  • Aiba Works Medical Research
  • Indian Council of Medical Research
  • Japan Agency for Medical Research and Development

Zitieren

APA

Kimura, T., Iwadare, T., Wakabayashi, S. I., Kuldeep, S., Nakajima, T., Yamazaki, T., Aomura, D., Zafar, H., Iwaya, M., Joshita, S., Uehara, T., Pydi, S. P., Tanaka, N., & Umemura, T. (2024). Thrombospondin 2 is a key determinant of fibrogenesis in non‐alcoholic fatty liver disease. Liver International, 44(2), 483-496. https://doi.org/10.1111/liv.15792

Vancouver

Kimura T, Iwadare T, Wakabayashi SI, Kuldeep S, Nakajima T, Yamazaki T, et al. Thrombospondin 2 is a key determinant of fibrogenesis in non‐alcoholic fatty liver disease. Liver International. 2024;44(2):483-496. doi:10.1111/liv.15792

BibTeX
@article{Kimura2024,
  author = {Kimura, Takefumi and Iwadare, Takanobu and Wakabayashi, Shun-Ichi and Kuldeep, Seema and Nakajima, Tomoyuki and Yamazaki, Tomoo and Aomura, Daiki and Zafar, Hamim and Iwaya, Mai and Joshita, Satoru and Uehara, Takeshi and Pydi, Sai P and Tanaka, Naoki and Umemura, Takeji},
  title = {Thrombospondin 2 is a key determinant of fibrogenesis in non‐alcoholic fatty liver disease},
  journal = {Liver International},
  year = {2024},
  volume = {44},
  number = {2},
  pages = {483--496},
  doi = {10.1111/liv.15792}
}
Kostenlos starten →